Md Farma Closes Series A Funding And Changes Name To Corganics As The Company Expands Clinical Cannabinoid (Cbd) Product Lines Sold Only In Healthcare Facilities
Md Farma Closes Series A Funding And Changes Name To Corganics As The Company Expands Clinical Cannabinoid (Cbd) Product Lines Sold Only In Healthcare Facilities
11/30/21, 11:17 AM
Location
dallasRound Type
series a
MD Farma, healthcare professionals' most trusted and recommended clinical cannabinoid (CBD) company, announced today a Series A investment from Altacrest Capital. The funding will support MD Farma's expansion of its clinical product portfolio, only available through healthcare professionals, and the company's branding strategy under its new name, Corganics. The new name reflects the company's commitment to all-natural, organic therapeutic products patients are actively seeking through healthcare professionals.
Company Info
Location
dallas, georgia, united states
Additional Info
Additionally, the company will acquire Relief™, a leading natural, non-CBD, topical pain analgesic product portfolio. With this funding round the company will accelerate its ability to reach more healthcare professionals by amplifying education on cannabinoid therapy, expanding operations, increasing its commercial footprint and investing in research and development innovations.